Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Bod Australia Ltd ( (AU:BOD) ).
Bod Science Limited announced the late lodgement of an Appendix 3Y ‘Change of Director’s Interest Notice’ for its executive director, Ms. Joanne Patterson, due to an administrative oversight. The company, currently under external administration, assures that this incident is isolated and that its current compliance practices are adequate. The late filing follows the cancellation of unlisted options due to unmet vesting conditions. Bod Science is under a Deed of Company Arrangement, with Andrew Barnden as the sole Deed Administrator, and remains committed to adhering to ASX Listing Rules.
More about Bod Australia Ltd
Bod Science Limited is a cannabis-focused drug development and product innovation company. It is committed to advancing research and development with a clear clinical trial pathway to commercialize and deliver premium, scientifically proven products for patients and consumers. The company collaborates with large corporate entities and leading research organizations to enhance the use of cannabis-related medicines with therapeutic indications.
Technical Sentiment Signal: Sell
Current Market Cap: A$4.26M
For detailed information about BOD stock, go to TipRanks’ Stock Analysis page.